Dmitry Balyasny’s Tango Therapeutics TNGX Stock Holding History

Dmitry Balyasny’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63M	Sell	2,016,379 -1,810,280	-47%	-$44.8M	0.08%	299
2026 Q1	$80.1M	Sell	3,826,659 -1,451,921	-28%	-$20.2M	0.1%	213
2025 Q4	$46.8M	Buy	5,278,580 +1,806,373	+52%	+$15.6M	0.06%	376
2025 Q3	$29.2M	Buy	3,472,207 +224,744	+7%	+$1.52M	0.04%	557
2025 Q2	$16.6M	Buy	3,247,463 +27,892	+0.9%	+$69K	0.03%	736
2025 Q1	$4.41M	Sell	3,219,571 -59,625	-2%	-$146K	0.01%	1306
2024 Q4	$10.1M	Buy	3,279,196 +592,000	+22%	+$2.75M	0.02%	956
2024 Q3	$20.7M	Buy	2,687,196 +2,410,187	+870%	+$23M	0.03%	612
2024 Q2	$2.38M	Buy	+277,009	New	+$2.14M	﹤0.01%	1468
2023 Q4	–	Sell	-844,377	Closed	-$9.51M	–	2906
2023 Q3	$9.51M	Buy	+844,377	New	+$5.15M	0.02%	862
2022 Q2	–	Sell	-31,781	Closed	-$241K	–	3185
2022 Q1	$241K	Buy	+31,781	New	+$275K	﹤0.01%	1981

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Dmitry Balyasny's TNGX Position: Q2 2026 in Review

Dmitry Balyasny reduced its Tango Therapeutics (TNGX) stake by 47% in Q2 2026, selling an estimated $44.8M and leaving 2,016,379 shares worth $63M. The position accounts for 0.08% of the portfolio, ranked #299.

Dmitry Balyasny first reported a position in TNGX in Q1 2022 and has held it in 11 quarters since. The position peaked at $80.1M in Q1 2026. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Dmitry Balyasny held 2,016,379 shares of Tango Therapeutics worth $63M as of Q2 2026.
Dmitry Balyasny sold 1,810,280 Tango Therapeutics shares in Q2 2026, an estimated $44.8M.
Tango Therapeutics made up 0.08% of Dmitry Balyasny's portfolio in Q2 2026, its #299 holding.
Dmitry Balyasny first reported a position in Tango Therapeutics in Q1 2022 and has held it in 11 quarters since.
Dmitry Balyasny's Tango Therapeutics position peaked at $80.1M in Q1 2026.
246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.